In a small study, a cancer vaccine assist beats immunotherapy drugs alone

The largest study to date of a "cancer vaccine" found that combining it with an immunotherapy drug kept patients’ tumors in check longer, on average, than the drug alone.

The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone, but that the benefit was still only a few months for two forms of cancer, study sponsor Neon Therapeutics reported on Monday.

It was a hint that an experimental therapy often described as the next great hope for immune-based approaches to fighting cancer will not be a silver bullet.

In the study, the 21 patients with metastatic bladder cancer, and the 27 with metastatic non-small-cell lung cancer, had a median progression-free survival (PFS) of 5.6 months, meaning half saw their tumors grow or spread before that time.

The 34 metastatic melanoma patients did dramatically better: After 13.4 months, the

You're reading a preview, sign up to read more.

More from STAT

STAT5 min readSociety
Opinion: Eliminating ‘Tensions’ In Health Care: A Litmus Test For Innovation
The challenge in applying the term innovation in health care is that the relationship between the "buyer" (patient) and the "seller" (provider) is convoluted by many other players.
STAT3 min readSociety
Opinion: Dreamers Like Me Fill Critical Gaps In Mental Health Care. The Dream And Promise Act Will Let Us Keep Doing That
Passing the American Dream and Promise Act to give Dreamers a pathway to citizenship would benefit not just the Dreamers but also the health care system and all of the…
STAT8 min readSociety
Mental Health Apps Are Scooping Up Your Most Sensitive Data. Will You Benefit?
Mental health apps can put patients’ privacy at risk, and makers of some tools are using the data collected to create products that have nothing to do with health care.